MedTrace Logo

X-linked Hypophosphatemia Disease Monitoring Program

NCT03651505 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 782

Last updated 2026-05-22

No results posted yet for this study

Summary

The objectives of this observational study are to characterize XLH disease presentation and progression and to assess long-term effectiveness and safety of burosumab.

Conditions

  • X-linked Hypophosphatemia
  • Hypophosphatemic Rickets

Interventions

OTHER

No intervention

Access to any treatment is through authorized commercial use and not as a part of this DMP

Sponsors & Collaborators

Principal Investigators

  • Ultragenyx Medical Director · Ultragenyx Pharmaceuticals Inc.

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-16
Primary Completion
2032-12-31
Completion
2032-12-31
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Brazil
  • Canada
  • Chile
  • Colombia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03651505 on ClinicalTrials.gov